S. 3716: Retaining Access and Restoring Exclusivity Act

This bill, titled the **Retaining Access and Restoring Exclusivity Act**, seeks to amend certain provisions related to the approval and licensing of drugs designated for rare diseases or conditions, also known as orphan drugs. The key aspects of the bill are outlined below:

1. Modification of Approval Language

The bill proposes changes to existing laws regarding orphan drugs. Currently, the language refers to drugs that treat the "same disease or condition." The new language will change this to refer to drugs that treat the "same approved use or indication within such rare disease or condition."

2. Changes to Exclusivity Period

The bill will adjust the rules around the exclusivity period that allows manufacturers of orphan drugs seven years of market exclusivity without competition. The modifications specify that this exclusivity applies to drugs for the "same approved use or indication" for which the exclusivity period was designated, rather than just the general "same rare disease or condition."

3. Clarification of Approved Use or Indication

The bill defines "approved use or indication" as the use that is officially approved under established laws for drugs designated for rare diseases. This aims to create clearer criteria for what constitutes an orphan drug eligible for exclusivity.

4. Applicability of Amendments

These amendments will apply to any orphan drug designated under the relevant section of the Federal Food, Drug, and Cosmetic Act, regardless of when it was designated or approved. This means that older drugs currently protected under the orphan drug exclusivity rules will also be subject to the new stipulations.

5. Implications for Drug Market Competition

The overarching goal of this legislation is to clarify and potentially shorten the exclusivity period for certain orphan drugs, thereby allowing other manufacturers to introduce competing drugs sooner. This is aimed at increasing market access and potentially reducing costs for patients needing treatments for rare diseases.

Relevant Companies

• VRTX - Vertex Pharmaceuticals: As a company known for its treatments for rare diseases, Vertex could be impacted if exclusivity periods are reduced for some of its orphan drugs.
• REGN - Regeneron Pharmaceuticals: This company also produces drugs for rare conditions and may see changes in its competitive landscape due to the proposed law.
• ALNY - Alnylam Pharmaceuticals: Alnylam’s focus on rare genetic diseases means its drug portfolio might be considered under the new exclusivity criteria.